Oxytocin

Dosing from the Literature

Published for mood and social use: nasal doses from trials with mixed results (Walum et al., 2016; Sikich et al., 2021); the approved doses are IV or IM, for labor and after birth (Pitocin label). Not published: an approved nasal dose in the US.

The table gives the doses on the Pitocin label, those used in the trials cited on this page, and, in the last row, what community reports describe.

What It Is

Oxytocin is a nine-amino-acid neuropeptide with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (molecular weight 1,007.19 Da), closed into a ring by a disulfide bridge between the cysteines at positions 1 and 6 (Pitocin label; Lawson et al., 2020). It differs from vasopressin (ADH) in only two amino acids, which the Pitocin label gives as the likely reason large doses of oxytocin can raise blood pressure and hold back water (Pitocin label).

Oxytocin is synthesized in magnocellular neurons of the hypothalamic (brain's hormonal control center) paraventricular nucleus (PVN) and supraoptic nucleus (SON) as part of the larger precursor protein oxytocin-neurophysin I. The mature peptide is transported along axons to the posterior pituitary (neurohypophysis), where it is released into peripheral circulation in response to parturition, suckling, stressors, and social stimuli. A second, central release pathway projects from PVN parvocellular neurons and dendritic somatodendritic release to forebrain targets including the amygdala, nucleus accumbens, hippocampus, and prefrontal cortex — the anatomical substrate for oxytocin's central behavioral effects.

Vincent du Vigneaud of Cornell synthesized oxytocin chemically in 1953, making it the first polypeptide hormone ever produced by total chemical synthesis. This achievement earned him the 1955 Nobel Prize in Chemistry and established oxytocin as the prototype for modern peptide pharmacology. Synthetic oxytocin was commercialized as Pitocin in the United States, today made for Par Health (Pitocin label), and as Syntocinon (Sandoz / Novartis) in Europe. Pitocin is FDA-approved for inducing labor when there is a medical reason, for strengthening labor, and for the third stage of labor and postpartum bleeding; its label states that it is not indicated for elective induction (Pitocin label). The intranasal Syntocinon formulation was historically used for initiating milk letdown during lactation, but has been discontinued in the United States (Novartis withdrew its FDA-registered intranasal Syntocinon in 1997) and is now manufactured in Europe primarily as an experimental research product.

Off-label and in psychiatric research, oxytocin is used mostly as a nasal spray, aimed at social cognition, anxiety, PTSD symptoms and autism-related social behavior; human studies have mostly used 20–48 IU, most often 24 IU (Quintana et al., 2021). This reflects the "nose-to-brain" pathway — olfactory and trigeminal intranasal delivery is thought to provide limited but meaningful access to CNS tissue while substantially bypassing the blood-brain barrier. The quantitative CSF-penetration fraction from intranasal dosing remains debated, with some studies showing measurable CSF oxytocin elevation after intranasal 24 IU and others showing minimal CSF penetration. This pharmacokinetic uncertainty is central to the replication controversies that surround the intranasal-oxytocin literature.

Mechanism of Action

Oxytocin acts mainly through its own receptor, OXTR, found in the uterus (Pitocin label) and in human brain areas including the central amygdala (Lawson et al., 2020); at high doses it may also act on vasopressin receptors (Quintana et al., 2021).

• Oxytocin receptor (OXTR) activation — In the uterus, oxytocin acts on its own receptors and raises calcium inside the muscle cells, which drives contraction through the calcium-dependent enzyme myosin light-chain kinase (Pitocin label). Its effects after nasal doses often do not rise in step with the dose; the cause is unknown, and one suggestion is that the receptor couples to different G proteins, or that high doses spill over onto vasopressin receptors (Quintana et al., 2021).
• Uterine and mammary peripheral signaling — Oxytocin receptors in the uterine muscle increase greatly during pregnancy and peak in early labor at term, so the uterus responds less to a given dose before term (Pitocin label). A nasal spray was once FDA-approved for lactation (Lawson et al., 2020).
• Central amygdala circuit modulation — Oxytocin receptors are found in the human central amygdala (Lawson et al., 2020). In 15 healthy men, a 27 IU nasal dose reduced amygdala activation to angry and fearful faces and threatening scenes on fMRI, and weakened the amygdala's coupling to brainstem regions involved in fear (Kirsch et al., 2005). A 2016 analysis judged intranasal studies generally underpowered and most published findings unlikely to be true effects (Walum et al., 2016).
• HPA-axis modulation — In 20 healthy men, a single 24 IU nasal dose lowered ACTH and cortisol before and after a meal (Ott et al., 2013).
• Mesolimbic dopamine and reward — In mice and rats, oxytocin receptors are found in the nucleus accumbens and the ventral tegmental area (Lawson et al., 2020), and one model holds that oxytocin shapes how salient social cues are through its interaction with the dopamine system (Shamay-Tsoory & Abu-Akel, 2016). In 20 healthy men, a single nasal dose cut snack eating driven by reward rather than hunger (Ott et al., 2013).
• Social salience framework — The modern mechanistic framing (Shamay-Tsoory 2016) is that oxytocin does not uniformly "promote prosocial behavior"; rather, it amplifies the salience of social information. The studies they review show effects on empathy, trust and in-group preference that depend on the setting and the person, including aggression and envy (Shamay-Tsoory & Abu-Akel, 2016); in three experiments in men, oxytocin raised trust and cooperation within the group and defensive, but not offensive, aggression toward a competing group (De Dreu et al., 2010).
• Metabolic signaling — Fat cells in culture carry oxytocin receptors; oxytocin raised fat breakdown (lipolysis) in these cells, in isolated fat tissue and in rats and monkeys, and chronic treatment cut fat mass in obese rodents, including visceral fat in obese mice (Lawson et al., 2020). In 25 healthy men, a single 24 IU nasal dose shifted fuel use from carbohydrate to fat and improved insulin sensitivity (Lawson et al., 2015).
• Cross-reactivity with vasopressin V1a/V2 receptors — In lab tests, oxytocin binds its own receptor 150 to 4,375 times more strongly than vasopressin receptors, though it may cross-react with the V2 receptor (Lawson et al., 2020). The Pitocin label notes that large doses can raise blood pressure and hold back water, which it puts down to oxytocin's similarity to vasopressin, and ties water intoxication with convulsions to large doses (40–50 mU/min) infused for long periods (Pitocin label).

What the Research Shows

Oxytocin's evidence falls into three parts: obstetric use of IV or IM oxytocin, where Cochrane reviewers graded the trials of a preventive dose after birth as very low to moderate in quality (Salati et al., 2019); a large but contested intranasal social-cognition literature, judged generally underpowered (Walum et al., 2016); and smaller metabolic and autism trials, including a 290-child autism trial that found no benefit (Sikich et al., 2021).

• Labor induction and augmentation (gold-standard evidence) — Pitocin has been FDA approved for labor induction and augmentation since 1962. For the third stage of labor, the label gives 10 units IM after delivery of the placenta (Pitocin label).
• Postpartum hemorrhage prevention — Cochrane reviews of a preventive dose in women giving birth vaginally found less bleeding of 500 mL or more and less need for additional uterotonics than with placebo or no uterotonic, on low- to moderate-quality evidence (Westhoff 2013, PMID 24173606; Salati 2019, PMID 31032882); the 2013 review's authors favored 10 IU as an IV bolus, or IM when IV is not possible. WHO's 2018 recommendations name oxytocin, 10 IU IM or IV, as the uterotonic of choice to prevent postpartum bleeding at every birth (Vogel et al., 2019; PMID 31139461).
• Intranasal oxytocin and amygdala reactivity (Kirsch et al., 2005; PMID 16339042) — Landmark fMRI paper: 27 IU intranasal oxytocin reduced amygdala BOLD response to fearful/angry faces in healthy males. Replicated with variable effect sizes across subsequent studies.
• Trust behavior (Kosfeld et al., 2005; PMID 15931222) — Influential early Nature paper: intranasal oxytocin increased monetary investment in an economic trust game. Subsequent replication attempts have produced mixed results, and the "oxytocin-increases-trust" narrative is now considered oversold.
• Emotion recognition and social cognition — Multiple small trials (Domes 2007; Guastella 2008; Bartz 2011) show intranasal oxytocin improves facial emotion recognition accuracy, particularly for subtle emotions. Effects are modest and most robust in individuals with baseline deficits.
• Autism spectrum disorder — small trials positive, 290-child trial negative — The SOARS-B multicenter phase 2 trial, funded by the US National Institute of Child Health and Human Development (Sikich et al., NEJM 2021; PMID 34644471), randomized 290 children and adolescents aged 3–17 with ASD to 24-week intranasal oxytocin vs placebo. Primary endpoint (Aberrant Behavior Checklist — modified Social Withdrawal) showed no significant difference between oxytocin and placebo. This trial substantially deflated the autism-intranasal-oxytocin hypothesis despite earlier positive smaller trials (Guastella 2010; Anagnostou 2012).
• Social anxiety disorder — Guastella et al. (2009) and subsequent trials showed modest reduction in self-reported anxiety during exposure therapy, with amygdala reactivity reduction on fMRI. Effect sizes are small-to-moderate; no regulatory submissions.
• PTSD — In 37 distressed people seen within 11 days of a trauma, a single 40 IU dose changed amygdala connectivity in a way the authors read as impeding emotion regulation, and flashbacks after trauma reminders were stronger; they urged caution about giving oxytocin to prevent PTSD (Frijling et al., 2016). No Phase 3 data; no regulatory pathway.
• Metabolic and obesity effects (Ott et al., 2013; PMID 23835346) — A single 24 IU intranasal dose cut reward-driven snack intake in healthy men, chocolate-cookie intake by 25%, and left hunger-driven intake at the test breakfast, energy expenditure and olfaction unchanged; it also blunted the meal-related rise in glucose and in ACTH and cortisol. In a small pilot trial in 20 men and women with overweight or obesity, nine of whom completed oxytocin, 24 IU before meals and at bedtime for eight weeks came with about 20 lb (9 kg) of weight loss and a 10 cm smaller waist (Lawson et al., 2020).
• Prader-Willi syndrome — Tauber, Miller, and colleagues have led multiple PWS trials showing intranasal oxytocin improves feeding behavior and social cognition in pediatric PWS, though effects remain modest.

Human Data

Oxytocin has one of the deepest human-evidence bases in peptide medicine, spanning obstetric, psychiatric, and metabolic indications:

• Pitocin obstetric use — FDA approved since 1962 — Foundational evidence for IV/IM oxytocin in labor induction, labor augmentation, and active management of third stage of labor. Cochrane reviews of a preventive dose after vaginal birth found less bleeding of 500 mL or more than with placebo or no uterotonic (Westhoff et al., 2013; Salati et al., 2019).
• Tureli et al., Pak J Med Sci 2026 (PMID 42819600) — Randomized and double-blind, at one hospital in Van, Turkey, in 2023–2024: 100 women aged 18–40 having an elective caesarean under general anaesthesia received, once the placenta was delivered, oxytocin (a 0.6 IU intravenous bolus, then 15 IU an hour) or carbetocin, a long-acting synthetic analogue of oxytocin (100 µg intravenously). Estimated blood loss during surgery averaged 522 mL on oxytocin and 421 mL on carbetocin, and 13 of 50 on oxytocin (26%) against 5 of 50 on carbetocin (10%) needed an extra uterotonic; apart from a lower mean arterial pressure at one minute on carbetocin, blood pressure and heart rate did not differ. The paper says five women were excluded for deep hypotension yet reports 50 in each group, and its authors list a single centre, general anaesthesia only and no follow-up after surgery as limits. No funding was declared.
• Kosfeld et al., Nature 2005 (PMID 15931222) — Intranasal oxytocin increased investment in a trust game. Foundational intranasal-oxytocin paper; replication mixed.
• Kirsch et al., J Neurosci 2005 (PMID 16339042) — 27 IU intranasal oxytocin reduced amygdala BOLD response to threat stimuli on fMRI in healthy males. Most reproducible imaging finding.
• Ott et al., Diabetes 2013 (PMID 23835346) — A single 24 IU intranasal dose cut reward-driven snack intake, but not breakfast intake, in 20 healthy men. Foundational metabolic-oxytocin paper.
• Sikich et al., NEJM 2021 (PMID 34644471) — SOARS-B multicenter phase 2 RCT of 290 children and adolescents with ASD randomized to 24-week intranasal oxytocin vs placebo. Primary endpoint (ABC-mSW) was negative. Its result constrained the autism indication.
• Guastella et al., Biol Psychiatry 2010 (PMID 19897177) — Randomized double-blind crossover in adolescent males with autism; single-dose intranasal oxytocin improved emotion recognition. Small N, subsequently not extrapolated to pivotal endpoints.
• Pedersen et al., Alcohol Clin Exp Res 2013 — Oxytocin and alcoholism withdrawal — Small pilot in alcohol-dependent patients showing reduced withdrawal symptoms.
• Feifel et al., Biol Psychiatry 2010 (PMID 20615494) — Adjunctive intranasal oxytocin in schizophrenia showed modest improvement in PANSS; not replicated in larger trials.
• Woolley et al., Mol Autism 2014 — Oxytocin and emotion recognition in ASD adults — Small positive trial; subsequently contextualized by SOARS-B pivotal negative finding.
• MacDonald et al., Psychoneuroendocrinology 2011 — Safety of intranasal oxytocin — Systematic review of 38 randomized trials of intranasal oxytocin (1990–2010): side effects did not differ from placebo.
• Walum et al., Biol Psychiatry 2016 (PMID 26210057) — Statistical power audit of the intranasal-oxytocin literature; argued most studies were underpowered and publication bias likely inflated effect sizes.

The practical summary: oxytocin is indispensable for obstetric use (IV/IM); intranasal oxytocin for central applications is a real but bounded intervention with effect sizes typically smaller than early-era claims, context-dependent responsiveness, and a negative 2021 phase 2 trial in the most-hyped psychiatric indication (autism).

Reconstitution & Storage

Pitocin comes ready-mixed at 10 USP units/mL in 1 mL single-dose and 10 mL multiple-dose vials, with chlorobutanol as preservative (Pitocin label). The Syntocinon nasal spray used in some trials holds 4 IU per 0.1 mL, or 40 IU/mL (Sikich et al., 2021); compounding pharmacies list nasal sprays at 20–100 IU/mL.

• Pitocin storage — The label lists storage at 20–25°C (68–77°F), controlled room temperature; for labor infusion it is diluted in 0.9% sodium chloride or Ringer's lactate, 10 units in 1,000 mL, giving 10 mU/mL (Pitocin label).
• Intranasal compounded storage — What compounding pharmacies list: refrigerated after opening, not frozen, with a shelf life of 30–90 days.
• Intranasal technique — In one trial, the 24 IU dose was given as six 0.1 mL puffs, three per nostril, 30 seconds apart (Ott et al., 2013). Critics have questioned how well common pump sprays deliver oxytocin to the brain through the maze-like nasal cavity (Quintana et al., 2021).
• Dosing timing for research paradigms — Studies measure effects 20–90 minutes after the dose (Quintana et al., 2021): the test breakfast came 45 minutes after it in one trial (Ott et al., 2013), and brain scanning began at 50 minutes in another (Kirsch et al., 2005).
• Inspection — The label describes Pitocin as a clear, colorless solution and says injectable products are checked for particles and discoloration before use (Pitocin label).

→ Calculator — vial-to-syringe math

Side Effects & Risks

The risks differ by route: the label's warnings cover IV and IM use in labor and after birth (Pitocin label), while nasal-spray trials found side effects not significantly more common than with placebo (Quintana et al., 2021).

• IV Pitocin — uterine hyperstimulation — Strong or prolonged contractions, or a resting tone of 15–20 mmHg or more between them, can lead to uterine rupture, tears, postpartum bleeding, reduced blood flow to the placenta and fetal heart-rate decelerations, hypoxia or death (Pitocin label). The label starts the infusion at a very low rate, monitors contractions and fetal heart rate throughout, and stops it at once for overactivity or fetal distress (Pitocin label).
• IV Pitocin — water intoxication / hyponatremia — Serious: oxytocin has an intrinsic antidiuretic effect, and the label warns of water intoxication, especially with continuous infusion while the patient also drinks; severe cases with convulsions and coma have followed a slow infusion over 24 hours, and maternal death has been reported (Pitocin label). For labor, the label dilutes it in 0.9% sodium chloride or Ringer's lactate (Pitocin label).
• IV Pitocin — blood pressure and heart rhythm — In childbirth, IV or IM oxytocin may change blood pressure and heart rate (Lawson et al., 2020). The label lists hypertensive episodes and cardiac arrhythmia among maternal adverse reactions, severe hypertension when oxytocin followed a vasoconstrictor given with caudal block anesthesia, and hypotension with cyclopropane anesthesia (Pitocin label).
• IV Pitocin — uterine rupture — Listed among maternal adverse reactions; maternal deaths from uterine rupture have been reported with oxytocic drugs used to induce or augment labor (Pitocin label). The label says oxytocin should not be given, except in unusual circumstances, where rupture is more likely, such as after major surgery on the cervix or uterus including cesarean section, with an overdistended uterus or in grand multiparity (Pitocin label).
• Intranasal — side effects in trials — Across nasal-spray trials, side effects were not significantly more common than with placebo (Quintana et al., 2021). In the 24-week autism trial, adverse events were about equally common with oxytocin and placebo (82% and 83%), but increased appetite (16% vs 10%), increased energy (10% vs 3%) and restlessness (8% vs 2%) were more frequent with oxytocin, and one serious event, sedation that led to a car accident, was judged related to it (Sikich et al., 2021).
• Intranasal — emotional reactivity changes — Its social effects depend on the setting and the person and can include aggression and envy (Shamay-Tsoory & Abu-Akel, 2016). In 37 distressed people seen within 11 days of a trauma, a 40 IU dose came with stronger flashbacks after trauma reminders (Frijling et al., 2016); in the autism trial, most stops for side effects were for irritability or aggression (Sikich et al., 2021).
• Intranasal — tolerance / receptor desensitization — No human data on tolerance are cited here. In obese rodents, oxytocin's cut in food intake faded with repeated or continuous dosing while weight loss continued, and continuous infusion into the brain reduced receptor binding (Lawson et al., 2020).
• Allergic / anaphylactoid reactions — The label lists anaphylactic reaction among maternal adverse reactions, and hypersensitivity to the drug as a contraindication (Pitocin label).
• Concurrent prostaglandin use — The labels of dinoprostone, a cervical-ripening prostaglandin, say it can strengthen oxytocin's effect: the vaginal insert is not used with IV oxytocin and comes out at least 30 minutes before oxytocin starts (Cervidil label), and the gel's label gives 6–12 hours before IV oxytocin (Prepidil label).
• Contraindications — Pitocin, before delivery: significant cephalopelvic disproportion; unfavorable fetal positions or presentations; obstetric emergencies that favor surgery; fetal distress when delivery is not imminent; an already hyperactive or hypertonic uterus; labor not progressing despite adequate contractions; conditions where vaginal delivery is contraindicated, such as total placenta previa, vasa previa or cord prolapse; and hypersensitivity to the drug (Pitocin label). No current US label covers nasal use.
• WADA status — Not named on the Prohibited List. Oxytocin is FDA-approved (Pitocin), so S0, which covers substances with no government approval, does not apply (WADA Prohibited List 2026).

Bloodwork & Monitoring

For IV use in labor, the Pitocin label calls for continuous observation by trained staff, electronic monitoring of contractions and fetal heart rate throughout the infusion, and attention to possible water intoxication when the infusion runs continuously and the patient is drinking (Pitocin label).

No trial, label or guideline sets monitoring for nasal oxytocin. The 24-week autism trial checked pulse, blood pressure, temperature, height and weight at every visit, and ECGs, urinalysis, blood chemistry, liver enzymes and prolactin at screening and week 24, and found no clinically meaningful changes (Sikich et al., 2021).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching oxytocin often also look at these:

Next Steps

References

1. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880. DOI: 10.1021/ja01115a553. (Original total chemical synthesis of oxytocin; basis of 1955 Nobel Prize in Chemistry.)
2. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005;25(49):11489-11493. PMID: 16339042.
3. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-676. PMID: 15931222.
4. Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, Hallschmid M. Oxytocin reduces reward-driven food intake in humans. Obesity (Silver Spring). 2013;21(10):2086-2090. Diabetes. 2013;62(10):3418-3425. PMID: 23835346.
5. Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, Spanos M, Chandrasekhar T, Trelles MDP, Rockhill CM, Palumbo ML, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med. 2021;385(16):1462-1473. PMID: 34644471. (SOARS-B — pivotal multicenter RCT in autism, primary endpoint negative.)
6. Walum H, Waldman ID, Young LJ. Statistical and Methodological Considerations for the Interpretation of Intranasal Oxytocin Studies. Biol Psychiatry. 2016;79(3):251-257. PMID: 26210057.
7. Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26(1):80-91. PMID: 32807845.
8. Lawson EA, Marengi DA, DeSanti RL, Holmes TM, Schoenfeld DA, Tolley CJ. Oxytocin Reduces Caloric Intake in Men. Obesity. 2015;23(5):950-956. PMID: 25865294.
9. Lawson EA, Olszewski PK, Weller A, Blevins JE. The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis. J Neuroendocrinol. 2020;32(4):e12805. PMID: 31657509.
10. Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2013;10:CD001808. PMID: 24173606.
11. Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2019;4:CD001808. PMID: 31032882.
12. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692-694. PMID: 19897177.
13. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mind-reading" in humans. Biol Psychiatry. 2007;61(6):731-733. PMID: 17137561.
14. Shamay-Tsoory SG, Abu-Akel A. The Social Salience Hypothesis of Oxytocin. Biol Psychiatry. 2016;79(3):194-202. PMID: 26321019.
15. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68(7):678-680. PMID: 20615494.
16. De Dreu CKW, Greer LL, Handgraaf MJJ, Shalvi S, Van Kleef GA, Baas M, Ten Velden FS, Van Dijk E, Feith SWW. The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans. Science. 2010;328(5984):1408-1411. PMID: 20538951.
17. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15(7):301-309. PMID: 21696997.
18. Tauber M, Boulanouar K, Diene G, Çabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, et al. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome. Pediatrics. 2017;139(2):e20162976. PMID: 28100688.
19. US Food and Drug Administration. Pitocin (oxytocin injection) prescribing information. FDA Approved Product Label. Accessed April 2026.
20. Frijling JL, van Zuiden M, Koch SBJ, Nawijn L, Veltman DJ, Olff M. Intranasal Oxytocin Affects Amygdala Functional Connectivity after Trauma Script-Driven Imagery in Distressed Recently Trauma-Exposed Individuals. Neuropsychopharmacology. 2016;41(5):1286-1296. PMID: 26346640.
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. Vogel JP, Williams M, Gallos I, Althabe F, Oladapo OT. WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ Glob Health. 2019;4(2):e001466. PMID: 31139461. (Sets out WHO's December 2018 recommendations: oxytocin 10 IU, IM or IV, for every birth.)
23. US Food and Drug Administration. Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications. Federal Register. 1997;62(152):42575-42577. federalregister.gov/d/97-20871. Read October 4, 2026. (Withdraws approval of NDA 12-285, Syntocinon nasal spray, Novartis, effective September 8, 1997, at the holder's request.)
24. Ferring Pharmaceuticals. Cervidil (dinoprostone) vaginal insert prescribing information. DailyMed set ID f3bc9031-0620-4a50-b440-f661cadfeb1d (version effective June 2, 2023). dailymed.nlm.nih.gov. Read October 4, 2026.
25. Pharmacia & Upjohn Company LLC. Prepidil (dinoprostone) cervical gel prescribing information. DailyMed set ID ab03de5b-782c-4f81-a8dc-7ef9969dd0cf (version effective October 22, 2025). dailymed.nlm.nih.gov. Read October 4, 2026.
26. Tureli B, Kurt N, Karaman E, Yuzkat N. Carbetocin versus oxytocin during elective cesarean delivery: A randomized double-blind trial. Pak J Med Sci. 2026;42(9):2227-2234. PMID: 42819600. DOI: 10.12669/pjms.42.9.13879. NCT06956365. (Open access; full text read.)

Related Research

• EpithalonPineal Tetrapeptide / Khavinson Bioregulator
• NAD+Mitochondrial + Longevity
• BronchogenKhavinson Bronchial Bioregulator
• CardiogenKhavinson Cardiac Bioregulator
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.